10.28.14
Mark Bisset has been promoted to president, Catalent Asia Pacific from Australian General Manager. He succeeds David Heyens who plans to retire on December 31, 2014.
Prior to joining the company, Mr. Bisset was chief executive officer for Strides Europe, leading commercial and manufacturing activities across multiple countries. He had previously spent four years as chief operating officer for Strides’ Australian and Asian businesses, overseeing several acquisitions including the successful integration of the ex-Genepharm business. He also held global business development and product management roles with Mayne Pharma Ltd., Amrad Pharmaceuticals Pty Ltd. and Bristol Myers Squibb.
“Mark assumes his new role at an exciting time of expansion in the region and we welcome him to the Executive Leadership Team,” said John Chiminski, Catalent’s president and chief executive officer. “We have made substantial investments in two joint ventures in China to serve our growing customer base there. Additionally, we are celebrating our 40th year in Japan with a new laboratory and the build-out of more manufacturing capacity, and are seeing strong market growth in these and other parts of the Asia Pacific region.”
Mr. Chiminski added, “I want to express my deep gratitude and respect for David’s service to Catalent. From when he joined R.P. Scherer Canada in 1995 as general manager of softgel, to ultimately becoming softgel business unit president in 2010, he has played a major role in our transformation into an advanced, drug delivery technology leader.”
Prior to joining the company, Mr. Bisset was chief executive officer for Strides Europe, leading commercial and manufacturing activities across multiple countries. He had previously spent four years as chief operating officer for Strides’ Australian and Asian businesses, overseeing several acquisitions including the successful integration of the ex-Genepharm business. He also held global business development and product management roles with Mayne Pharma Ltd., Amrad Pharmaceuticals Pty Ltd. and Bristol Myers Squibb.
“Mark assumes his new role at an exciting time of expansion in the region and we welcome him to the Executive Leadership Team,” said John Chiminski, Catalent’s president and chief executive officer. “We have made substantial investments in two joint ventures in China to serve our growing customer base there. Additionally, we are celebrating our 40th year in Japan with a new laboratory and the build-out of more manufacturing capacity, and are seeing strong market growth in these and other parts of the Asia Pacific region.”
Mr. Chiminski added, “I want to express my deep gratitude and respect for David’s service to Catalent. From when he joined R.P. Scherer Canada in 1995 as general manager of softgel, to ultimately becoming softgel business unit president in 2010, he has played a major role in our transformation into an advanced, drug delivery technology leader.”